Miniatura

Fitxers

715041.pdf (543.57 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-02-04

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/180762

A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJMoa2021801

Resum

Background: current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking. Methods: we conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days. Results: the analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported. Conclusions: postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.).

Matèries

Agents antiinfecciosos, Ús terapèutic, COVID-19

Matèries (anglès)

Anti-infective agents, Therapeutic use, COVID-19

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)

Citació

MITJÀ VILLAR, Oriol, CORBACHO-MONNÉ, Marc, UBALS CAZORLA, Maria, ALEMANY ORTIZ, Andrea, SUÑER NAVARRO, Clara, TEBÉ, Cristian, TOBIAS, Aurelio, PEÑAFIEL, Judith, BALLANA, Ester, PÉREZ, Carla a., ADMELLA, Pol, RIERA-MARTÍ, Núria, LAPORTE, Pep, MITJÀ, Jordi, CLUA, Mireia, BERTRAN, Laia, SARQUELLA, Maria, GAVILÁN, Sergi, ARA, Jordi, ARGIMÓN PALLÁS, José m., CUATRECASAS, Gabriel, CAÑADAS, Paz, ELIZALDE TORRENT, Aleix, FABREGAT, Robert, FARRÉ ALBALADEJO, Magí, FORCADA, Anna, FLORES MATEO, Gemma, LÓPEZ GONZÁLEZ, Cristina, MUNTADA, Esteve, NADAL, Núria, NAREJOS, Silvia, NIETO, Aroa, PRAT, Núria, PUIG, Jordi, QUIÑONES, Carles, RAMÍREZ-VIAPLANA, Ferran, REYES URUEÑA, Juliana, RIVEIRA MUÑOZ, Eva, RUIZ SAINZ, Lidia, SANZ, Sergi. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. _New England Journal of Medicine_. 2021. Vol. 384, núm. 5, pàgs. 417-427. [consulta: 2 de abril de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/180762]

Exportar metadades

JSON - METS

Compartir registre